Staff Profile

Edit

Career Summary

Qualifications

  • Bachelor of Mathematics, University of Newcastle, 02/05/1987

Research

Research keywords

  • clinical trials
  • prostate cancer

Research expertise

Since 2003 I have the trial coordinator of the TROG 96.01 prostate cancer trial.

Fields of Research

CodeDescriptionPercentage
029999Physical Sciences Not Elsewhere Classified50
110399Clinical Sciences Not Elsewhere Classified25
111200Oncology And Carcinogenesis25
Edit

Highlighted Publications

For publications that are currently unpublished or in-press, details are shown in italics.

YearCitationAltmetricsLink
2005Denham J, Steigler A, Lamb D, Joseph D, Mameghan H, Turner S, et al., 'Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer : results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial', The Lancet, 6 841-850 (2005) [C1]

As a result of the findings published in this article clinical practice has changed for the treatment of locally advanced prostate cancer in Australia and New Zealand. The article now has over 100 citations.

2008Denham J, Steigler A, Wilcox C, Lamb DS, Joseph D, Atkinson C, et al., 'Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial', Lancet Oncology, 9 1058-1068 (2008) [C1]

This is a journal with high impact factor. Our paper reports on a very important clinical trial issue (surrogates) and we have employed very robust high level statistical analyses.

Publications

For publications that are currently unpublished or in-press, details are shown in italics.

Click on a category title below to expand the list of citations for that specific category.

Journal article (28 outputs)

YearCitationAltmetricsLink
2014Denham JW, Mcelduff P, Steigler A, Kautto A, Ball J, Nowitz M, et al., 'Impact of androgen suppression and zoledronic acid on bone mineral density and fractures in the Trans-Tasman Radiation Oncology Group (TROG) 03.04 Randomised Androgen Deprivation and Radiotherapy (RADAR) randomized controlled trial for locally advanced prostate cancer', BJU International, (2014)
2013Denham JW, Steigler A, 'Picking the Optimal Duration of Hormonal Therapy in Men With High-Risk and Locally Advanced Prostate Cancer Treated With Radiotherapy', Seminars in Radiation Oncology, 23 206-214 (2013) [C1]
2013Denham JW, Steigler A, Tai K, Joseph D, Matthews J, Atkinson C, et al., 'Paradoxical metastatic progression following 3 months of neo-adjuvant androgen suppression in the TROG 96.01 trial for men with locally advanced prostate cancer', Radiotherapy and Oncology, 107 123-128 (2013) [C1]
2012Steigler A, Denham J, Lamb DS, Spry NA, Joseph D, Matthews J, et al., 'Risk stratification after biochemical failure following curative treatment of locally advanced prostate cancer: Data from the TROG 96.01 trial', Prostate Cancer, 2012 1-11 (2012) [C1]
2012Wilcox C, Kautto AJ, Steigler A, Denham J, 'Androgen deprivation therapy for prostate cancer does not increase cardiovascular mortality in the long term', Oncology: International Journal of Cancer Research and Treatment, 82 56-58 (2012) [C1]
2012D'Amico AV, Chen M-H, De Castro M, De Castro M, Lamb DS, Steigler A, et al., 'Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: An analysis of two randomised trials', Lancet Oncology, 13 189-195 (2012) [C1]
2011Lamb DS, Denham J, Joseph D, Matthews J, Atkinson C, Spry NA, et al., 'A comparison of the prognostic value of early PSA test-based variables following external beam radiotherapy, with or without preceding androgen deprivation: Analysis of data from the TROG 96.01 randomized trial', International Journal of Radiation Oncology Biology Physics, 79 385-391 (2011) [C1]
2011D'Amico AV, Chen MH, Crook J, Armstrong JG, Malone S, Steigler A, et al., 'Duration of short-course androgen suppression therapy and the risk of death as a result of prostate cancer', Journal of Clinical Oncology, 29 4682-4687 (2011) [C1]
2011Denham J, Steigler A, Lamb DS, Joseph D, Turner S, Matthews J, et al., 'Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial', The Lancet Oncology, 12 451-459 (2011) [C1]
2011Ebert MA, Lamb DS, Joseph DJ, Steigler A, Denham J, 'A methodology for the analysis of PSA response signatures', Radiotherapy and Oncology, 98 198-202 (2011) [C1]
2011Denham J, Lamb DS, Joseph D, Matthews J, Atkinson C, Spry NA, et al., 'Another form of subgroup to beware', Radiotherapy and Oncology, 101 525-526 (2011) [C3]
2010Kumar M, Denham J, Steigler A, 'Value of combined androgen blockade in the neoadjuvant treatment of localized prostate cancer: The jury must remain out', Journal of Clinical Oncology, 28 E445-E446 (2010) [C3]
2009Capp A, Inostroza-Ponta M, Bill D, Moscato PA, Lai C, Christie D, et al., 'Is there more than one proctitis syndrome? A revisitation using data from the TROG 96.01 trial', Radiotherapy and Oncology, 90 400-407 (2009) [C1]
2009Denham J, Lamb DS, Joseph D, Matthews J, Atkinson C, Spry NA, et al., 'PSA response signatures: A powerful new prognostic indicator after radiation for prostate cancer?', Radiotherapy and Oncology, 90 382-388 (2009) [C1]
2009Denham J, Kumar M, Gleeson PS, Lamb DS, Joseph D, Atkinson C, et al., 'Recognizing false biochemical failure calls after radiation with or without neo-adjuvant androgen deprivation for prostate cancer', International Journal of Radiation Oncology Biology Physics, 74 404-411 (2009) [C1]
2009Denham J, Steigler A, Wilcox C, Lamb DS, Joseph D, Atkinson C, et al., 'Why are pretreatment prostate-specific antigen levels and biochemical recurrence poor predictors of prostate cancer survival?', Cancer, 115 4477-4487 (2009) [C1]
2009Denham J, Steigler A, Kumar M, Lamb DS, Joseph D, Spry NA, et al., 'Measuring time to biochemical failure in the Trog 96.01 trial: When should the clock start ticking?', International Journal of Radiation Oncology Biology Physics, 75 1008-1012 (2009) [C1]
2008Denham J, Steigler A, Wilcox C, Lamb DS, Joseph D, Atkinson C, et al., 'Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial', Lancet Oncology, 9 1058-1068 (2008) [C1]

This is a journal with high impact factor. Our paper reports on a very important clinical trial issue (surrogates) and we have employed very robust high level statistical analyses.

2007D'Amico AV, Denham J, Bolla M, Collette L, Lamb DS, Tai KH, et al., 'Short- vs long-term androgen suppression plus external beam radiation therapy and survival in men of advanced age with node-negative high-risk adenocarcinoma of the prostate', Cancer, 109 2004-2010 (2007) [C1]
2007D'Amico AV, Denham J, Crook J, Chen MH, Goldhaber SZ, Lamb DS, et al., 'Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions', Journal of Clinical Oncology, 25 2420-2425 (2007) [C1]
2005Denham J, Steigler A, Lamb D, Joseph D, Mameghan H, Turner S, et al., 'Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer : results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial', The Lancet, 6 841-850 (2005) [C1]

As a result of the findings published in this article clinical practice has changed for the treatment of locally advanced prostate cancer in Australia and New Zealand. The article now has over 100 citations.

2005Back M, Ahern V, Delaney G, Graham P, Steigler A, Wratten C, 'Absence of adverse early quality of life outcomes of radiation therapy in breast conservation therapy for early breast cancer', Journal of Medical Imaging and Radiation Oncology, 49 39-43 (2005) [C1]
2005Christie D, Denham J, Steigler A, Lamb D, Turner S, Mameghan H, et al., 'Delayed rectal and urinary symptomatology in patients treated for prostate cancer by radiotherapy with or without short term neo-adjuvant androgen deprivation', Radiotherapy and oncology, 77 117-125 (2005) [C1]
2005Danham JW, Steigler A, Lamb DS, Joseph D, Turner S, Matthews J, et al., 'TROG 96.01: first report of the main endpoints', EJC SUPPLEMENTS, 3 230-231 (2005)
2004Back M, Guerrieri M, Wratten C, Steigler A, 'Impact of radiation therapy on acute toxicity in breast conservation therapy for early breast cancer', CLINICAL ONCOLOGY, 16 12-16 (2004)
2003Denham J, Steigler A, Kilmurray J, Wratten C, Burmeister B, Lam D, et al., 'Relapse patterns after chemo-radiation for carcinoma of the oesophagus', Clinical Oncology, 15 98-108 (2003) [C1]
2000Steigler A, Mameghan H, Lamb D, Joseph D, Matthews J, Franklin I, et al., 'A quality assurance audit: Phase 111 trial of maximal androgen deprivation in prostate cancer (TROG 96.01)', AUSTRALASIAN RADIOLOGY, 44 65-71 (2000) [C1]
1999Hamilton C, Poulsen M, Walker Q, Krawitz H, Hindley A, Spry N, et al., 'Quality assurance audit in an Australasian phase III trial of accelerated radiotherapy for head and neck cancer (TROG 91.01). Trans-Tasman Radiation Oncology Group.', Australas Radiol, 43 227-232 (1999)
Show 25 more

Conference (8 outputs)

YearCitationAltmetricsLink
2011Denham J, Steigler A, Lamb DS, Joseph DJ, Matthews J, Atkinson C, et al., 'Variations in androgen dependent clinical progression kinetics in locally advanced prostate cancer', European Journal of Cancer, Stockholm, Sweden (2011) [E3]

Co-authors: Catherine DEste

2007Denham J, Joseph D, Lamb D, Tai KH, Turner S, Matthews J, et al., 'Reasons for initial PSA (iPSA) and biochemical failure (BF) being poor predictors of prostate cancer (PC) mortality', European Journal of Cancer Supplements (ECCO 14 Abstract Book), Barcelona, Spain (2007) [E3]
2006Joseph D, Denham J, Lamb D, Tai K, Turner S, Matthews J, et al., 'The biological significance of longitudinal changes in PSA; PSA response signatures (PRS)', Proceedings of the 48th Annual Meeting of the American Society for Therapeutic Radiology and Oncology, 48th Annual Meeting of the American Society for Therapeutic Radiology and Oncology, Philadelphia, PA (2006) [E3]
2006Lamb D, Denham J, Joseph D, Tai K, Turner S, Matthews J, et al., 'The biological significance of longitudinal changes in PSA: Post treatment variations and mistaken biochemical failure', Proceedings of the 48th Annual Meeting of the American Society for Therapeutic Radiology and Oncology, 48th Annual Meeting of the American Society for Therapeutic Radiology and Oncology, Philadelphia, PA (2006) [E3]
2006Denham J, Joseph D, Lamb D, Tai K, Turner S, Matthews J, et al., 'The biological significance of longitudinal changes in PSA; Doubling time during biochemical failure', Proceedings of the 48th Annual Meeting of the American Society for Therapeutic Radiology and Oncology, 48th Annual Meeting of the American Society for Therapeutic Radiology and Oncology, Philadelphia, PA (2006) [E3]

Co-authors: Peter Greer

2006Joseph D, Lamb D, Denham J, Tai K-H, Turner S, Matthews J, et al., 'The biological significance of longitudinal changes in PSA; Post treatment variation sand mistaken biochemical failure.', RADIOTHERAPY AND ONCOLOGY, Leipzig, GERMANY (2006)
2006Lamb D, Denham J, Joseph D, Tai K, Turner S, Matthews J, et al., 'The biological significance of longitudinal changes in PSA; Post treatment variations and mistaken biochemical failure', INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, Philadelphia, PA (2006)
2006Denham J, Joseph D, Lamb D, Tai K-H, Turner S, Matthews J, et al., 'The biological significance of longitudinal changes in PSA; Doubling time during biochemical failure', RADIOTHERAPY AND ONCOLOGY, Leipzig, GERMANY (2006)
Show 5 more
Edit

Grants and Funding

Summary

Number of grants1
Total funding$399,565

- Indicates that the researcher may be seeking students for this project.

Click on a grant title below to expand the full details for that specific grant.

2007 (1 grants)

Optimal duration of neoadjuvant androgen deprivation therapy in localised prostate cancer$399,565
Funding Body: NHMRC (National Health & Medical Research Council)

Project Team
Conjoint Professor Jim Denham, Mrs Allison Steigler
SchemeRole
Project GrantInvestigator
Total AmountFunding StartFunding Finish
$399,56520072011
GNo:G0186389
Edit

Research Supervision

Number of current supervisions0

No Supervisions.

Edit

Mrs Allison Steigler

Work Phone(02) 4985 4019
Fax(02) 4968 4924
Email
PositionStatistician
Prostate Cancer Clinical Trials Group
School of Medicine and Public Health
Faculty of Health and Medicine
The University of Newcastle, Australia
Office
WTPO 118,
Waratah Post Office,
Other
URL:www.newcastle.edu.au/profile/allison-steigler